search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Pharma: Outsourcing


www.chemicalsknowledgehub.com


What type of pharma machinery will pharma manufacturers invest in the most in 2021?


Filling and packaging systems were voted as the machinery type that pharma manufacturers will invest in the most in 2021, taking 24% of the vote. The underlying reason cited for this was the expansion and modernization of finished dose manufacturing. For example, dug production is gradually moving closer to the point of consumption and drug product CMOs/ CDMOs are investing to become one-stop-shops in a move to aid innovator desires to simplify and streamline outsourcing. This is of course not to mention the huge logistical challenge of filling billions of Covid vaccines. As in previous years (pre-Covid), large-scale bioreactors and fermenters were the second most popular choice, with 13% of votes. Manufacturers will look to expand their capabilities and capacity for biologicals and capitalize on the impending wave of biologics approvals over the next few years. Other popular machinery types included small- molecule reactors (12%), purification systems (9%) and single-use bioreactors (8%).


What is the most important factor when buying machinery? Significantly, unlike the cost-based decisions often seen in other areas, 53% of respondents stated that ‘quality of machinery and lifespan’ are the most important factors when buying machinery, whilst 24% believe it to be reliability. 11% and 8% of respondents believed flexibility in use and cost to be the most important factors, respectively.


Already in 2021, in just the first few weeks/ months of approvals, we are seeing innovators struggle to scale production to meet demand. Further vaccine approvals are also expected in Q1 and Q2 of this year, increasing capacity constraints and overall pharmaceutical production volumes. This, however, has already resulted in another huge opportunity for CDMOs and biological manufacturers with Serium Institute of India, Wacker, Emergent BioSolutions, Avid Bioservices, Lonza, Delpharm, Catalent, Recipharm and HALIX as just a few of the companies that have received sizable outsourcing contracts. In fact, PharmSource estimates that globally more than 6 billion doses will now be produced in 2021 . Yet despite these favourable headwinds heading into 2021, 20% of respondents believe that the business outlook will remain the same, with 19% believing pharma’s outlook has decreased, perhaps reflecting the wider


26


economic uncertainty and disparities between how well different economies have managed to maintain growth and, in the longer term, more importantly, how employment levels may affect structural deficits in Western economies.


Further information


For more key insights and post-pandemic trends, download the CPhI Post Pandemic Legacy Trends Report on https://www.cphi- online.com/this-special-cphi-report-is-split- into-two-halves-file113613.html


March/April 2021 • Issue 2


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64